Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec;14(12):1259-70.
doi: 10.1016/S1473-3099(14)70821-7. Epub 2014 Sep 8.

Antiviral combinations for severe influenza

Jake Dunning  1 , J Kenneth Baillie  2 , Bin Cao  3 , Frederick G Hayden  4 ; International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)
Affiliations
Review

Antiviral combinations for severe influenza

Jake Dunning et al. Lancet Infect Dis. 2014 Dec.

Erratum in

  • Lancet Infect Dis. 2014 Dec;14(12):1174

Abstract

Observational data suggest that the treatment of influenza infection with neuraminidase inhibitors decreases progression to more severe illness, especially when treatment is started soon after symptom onset. However, even early treatment might fail to prevent complications in some patients, particularly those infected with novel viruses such as the 2009 pandemic influenza A H1N1, avian influenza A H5N1 virus subtype, or the avian influenza A H7N9 virus subtype. Furthermore, treatment with one antiviral drug might promote the development of antiviral resistance, especially in immunocompromised hosts and critically ill patients. An obvious strategy to optimise antiviral therapy is to combine drugs with different modes of action. Because host immune responses to infection might also contribute to illness pathogenesis, improved outcomes might be gained from the combination of antiviral therapy with drugs that modulate the immune response in an infected individual. We review available data from preclinical and clinical studies of combination antiviral therapy and of combined antiviral-immunomodulator therapy for influenza. Early-stage data draw attention to several promising antiviral combinations with therapeutic potential in severe infections, but there remains a need to substantiate clinical benefit. Combination therapies with favourable experimental data need to be tested in carefully designed aclinical trials to assess their efficacy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO Influenza (seasonal). Fact sheet; March, 2014. http://www.who.int/mediacentre/factsheets/fs211/en/index.html (accessed June 23, 2014).
    1. Health Protection Agency Surveillance of influenza and other respiratory viruses in the UK: 2010–2011. May, 2011 report. http://www.hpa.org.uk/Publications/InfectiousDiseases/Influenza/1105infl... (accessed June 23, 2014).
    1. Centers for Disease Control and Prevention Seasonal influenza (flu). 2013–2014 influenza season week 18 ending May 3, 2014. http://www.cdc.gov/flu/weekly/ (accessed June 23, 2014).
    1. European Centre For Disease Prevention and Control Human infection with a novel avian influenza A(H7N9) virus, China. Third update; Jan 27, 2014. http://www.ecdc.europa.eu/en/publications/Publications/influenza-AH7N9-C... (accessed June 23, 2014).
    1. Chen H, Yuan H, Gao R. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet. 2014;383:714–721. - PubMed

MeSH terms